Pharmacologic therapy for osteoarthritis-the era of disease modification

Nature Reviews Rheumatology

Volumn 7, Issue 1, 2011, Pages 13-22

  Hunter, David J ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CHONDROITIN SULFATE; COLECALCIFEROL; COLLAGEN HYDROLYZATE; COLLAGENASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DERMATAN SULFATE; DIACEREIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; FIBROBLAST GROWTH FACTOR 18; GLUCOSAMINE; GLUCOSAMINE SULFATE; HYALURONIC ACID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LICOFELONE; MATRIX METALLOPROTEINASE INHIBITOR; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOGENIC PROTEIN 1; PG 116800; PIASCLEDINE; PLACEBO; PRALNACASAN; PROTEIN HYDROLYSATE; RECOMBINANT FIBROBLAST GROWTH FACTOR; RISEDRONIC ACID; SALCATONIN; SD 6010; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTHRALGIA; ARTHROSCOPY; BODY BURDEN; CARTILAGE DEGENERATION; CHONDROPROTECTION; CLINICAL DEVELOPMENT PLAN; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; ECHOGRAPHY; ENZYME INHIBITION; FOLLOW UP; HEALTH PROGRAM; HIP OSTEOARTHRITIS; HUMAN; JOINT FUNCTION; JOINT PROSTHESIS; JOINT RADIOGRAPHY; MUSCULOSKELETAL DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PAIN THRESHOLD; PALLIATIVE THERAPY; PATHOGENESIS; PHYSICAL DISABILITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; BIOMECHANICS; DISEASE PROGRESSION; DRUG THERAPY; HUMANS; OSTEOARTHRITIS; TREATMENT OUTCOME;

EID: 78650986866     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.178     Document Type: Review

References (116)

1. Nuki, G. Osteoarthritis: a problem of joint failure. Z. Rheumatol. 58, 142-147 (1999).
2. Eyre, D. R. Collagens and cartilage matrix homeostasis. Clin. Orthop. Relat. Res. 427 (Suppl.), S118-S122 (2004).
3. Dillon, C. F., Rasch, E. K., Gu, Q. & Hirsch, R. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991-94. J. Rheumatol. 33, 2271-2279 (2006).
4. Centers for Disease Control and Prevention (CDC). Prevalence and impact of chronic joint symptoms-seven states, 1996. MMWR Morb. Mortal. Wkly Rep. 47, 345-351 (1998).
5. Dunlop, D. D., Manheim, L. M., Song, J. & Chang, R. W. Arthritis prevalence and activity limitations in older adults. Arthritis Rheum. 44, 212-221 (2001).
6. Lawrence, R. C. et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41, 778-799 (1998).
7. Zhang, Y. et al. Prevalence of symptomatic hand osteoarthritis and its impact on functional status among the elderly: the Framingham Study. Am. J. Epidemiol. 156, 1021-1027 (2002).
8. Centers for Disease Control and Prevention (CDC). Prevalence of disabilities and associated health conditions among adults-United States, 1999. MMWR Morb. Mortal. Wkly Rep. 50, 120-125 (2001).
9. Guccione, A. A. et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am. J. Public Health 84, 351-358 (1994).
10. Centers for Disease Control and Prevention (CDC). Arthritis prevalence and activity limitations-United States, 1990. MMWR Morb. Mortal. Wkly Rep. 43, 433-438 (1994).
11. Felson, D. T. An update on the pathogenesis and epidemiology of osteoarthritis. Radiol. Clin. North Am. 42, 1-9 (2004).
12. Blagojevic, M., Jinks, C., Jeffery, A. & Jordan, K. P. Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. Osteoarthritis Cartilage 18, 24-33 (2010).
13. Yoo, J. H. et al. A meta-analysis of the effect of neuromuscular training on the prevention of the anterior cruciate ligament injury in female athletes. Knee Surg. Sports Traumatol. Arthrosc. 18, 824-830 (2010).
14. Glazier, R. H. et al. Management of common musculoskeletal problems: a survey of Ontario primary care physicians. CMAJ 158, 1037-1040 (1998).
15. Hunter, D. J. Are there promising biologic therapies for osteoarthritis? Curr. Rheumatol. Rep. 10, 19-25 (2008).
16. Desai, S. P. et al. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum. 59, 1058-1073 (2008).
17. Hunter, D. J., Le Graverand, M. P. & Eckstein, F. Radiologic markers of osteoarthritis progression. Curr. Opin. Rheumatol. 21, 110-117 (2009).
18. Verbruggen, G. Chondroprotective drugs in degenerative joint diseases. Rheumatology (Oxford) 45, 129-138 (2006).
19. Hunter, D. J. & Hellio Le Graverand- Gastineau, M. P. How close are we to having structure-modifying drugs available? Rheum. Dis. Clin. North Am. 34, 789-802 (2008).
20. Le Graverand-Gastineau, M. P. Disease modifying osteoarthritis drugs: facing development challenges and choosing molecular targets. Curr. Drug Targets 11, 528-535 (2010).
21. Abramson, S. B., Attur, M. & Yazici, Y. Prospects for disease modification in osteoarthritis. Nat. Clin. Pract. Rheumatol. 2, 304-312 (2006).
22. Brandt, K. D. et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum. 52, 2015-2025 (2005).
23. Dougados, M. et al. Evaluation of the structuremodifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum. 44, 2539-2547 (2001).
24. OARSI FDA OA initiative. www.oarsi.org [online], http://www.oarsi.org/ index2.cfm?section= OARSI-Initiatives&content=FDA-OA-Initiative (2009).
25. Wieland, H. A., Michaelis, M., Kirschbaum, B. J. & Rudolphi, K. A. Osteoarthritis-an untreatable disease? Nat. Rev. Drug Discov. 4, 331-344 (2005).
26. Jacobsen, S. & Sonne-Holm, S. Hip dysplasia: a significant risk factor for the development of hip osteoarthritis. A cross-sectional survey. Rheumatology (Oxford) 44, 211-218 (2005).
27. Utting, M. R., Davies, G. & Newman, J. H. Is anterior knee pain a predisposing factor to patellofemoral osteoarthritis? Knee 12, 362-365 (2005).
28. Karlson, E. W. et al. Total hip replacement due to osteoarthritis: the importance of age, obesity, and other modifiable risk factors. Am. J. Med. 114, 93-98 (2003).
29. Flugsrud, G. B. et al. The impact of body mass index on later total hip arthroplasty for primary osteoarthritis: a cohort study in 1.2 million persons. Arthritis Rheum. 54, 802-807 (2006).
30. Felson, D. T. The sources of pain in knee osteoarthritis. Curr. Opin. Rheumatol. 17, 624-628 (2005).
31. Hunter, D. J. et al. A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials. Curr. Drug Targets 11, 536-545 (2010).
32. Gossec, L. et al. OMERACT/OARSI initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. J. Rheumatol. 34, 1432-1435 (2007).
33. Lassere, M. N. A users guide to measurement in medicine. Osteoarthritis Cartilage 14 (Suppl. A), A10-A13 (2006).
34. Clinical development programs for drugs, devices, and biological products intended for the treatment of osteoarthritis (OA). www.fda.gov [online], http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm071577.pdf (1999)
35. Eckstein, F. et al. Proposal for a nomenclature for magnetic resonance imaging based measures of articular cartilage in osteoarthritis. Osteoarthritis Cartilage 14, 974-983 (2006).
36. Kraus, V. B. & Burnett, B. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage (in press).
37. Ornetti, P. et al. OARSI-OMERACT definition of relevant radiological progression in hip/knee osteoarthritis. Osteoarthritis Cartilage 17, 856-863 (2009).
38. Guermazi, A. et al. Imaging in osteoarthritis. Rheum. Dis. Clin. North Am. 34, 645-687 (2008).
39. Brandt, K. D., Radin, E. L., Dieppe, P. A. & van de Putte, L. Yet more evidence that osteoarthritis is not a cartilage disease. Ann. Rheum. Dis. 65, 1261-1264 (2006).
40. Papaioannou, N. A. et al. Effect of calcitonin in early and late stages of experimentally induced osteoarthritis. A histomorphometric study. Osteoarthritis Cartilage 15, 386-395 (2007).
41. Karsdal, M. A. et al. Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA? Osteoarthritis Cartilage 14, 617-624 (2006).
42. Karsdal, M. A., Sondergaard, B. C., Arnold, M. & Christiansen, C. Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis? Ann. NY Acad. Sci. 1117, 181-195 (2007).
43. Schnitzer, T. J. New pharmacologic approaches in the management of osteoarthritis. Arthritis Care Res. (Hoboken) 62, 1174-1180 (2010).
44. Karsdal, M. A. et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. Osteoarthritis Cartilage 18, 150-159 (2010).
45. Karsdal, M. A., Henriksen, K., Arnold, M. & Christiansen, C. Calcitonin: a drug of the past or for the future- Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. BioDrugs 22, 137-144 (2008).
46. Manicourt, D. H., Azria, M., Mindeholm, L., Thonar, E. J. & Devogelaer, J. P. Oral salmon calcitonin reduces Lequesnes algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum. 54, 3205-3211 (2006).
47. Efficacy and safety of oral salmon calcitonin in patients with knee osteoarthritis. ClinicalTrials.gov identifier: NCT00486434 [online], http:// clinicaltrials.gov/ct2/show/NCT00486434 (2010)
48. Efficacy and safety of oral salmon calcitonin in patients with knee osteoarthritis (OA 2 study). ClinicalTrials.gov identifier: NCT00704847 [online], http://clinicaltrials.gov/ct2/show/ NCT00704847 (2010).
49. Abramson, S. B. Nitric oxide in inflammation and pain associated with osteoarthritis. Arthritis Res. Ther. 10 (Suppl. 2), S2 (2008).
50. A long-term, placebo-controlled X-ray study investigating the safety and efficacy of SD-6010 in subjects with osteoarthritis of the knee (ITIC). ClinicalTrials.gov identifier: NCT00565812 [online], http://clinicaltrials.gov/ ct2/show/ NCT00565812 (2010).
51. Vuolteenaho, K., Moilanen, T., Knowles, R. G. & Moilanen, E. The role of nitric oxide in osteoarthritis. Scand. J. Rheumatol. 36, 247-258 (2007).
52. Griffith, D. L., Keck, P. C., Sampath, T. K., Rueger, D. C. & Carlson, W. D. Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily. Proc. Natl Acad. Sci. USA 93, 878-883 (1996).
53. Massagué, J., Attisano, L. & Wrana, J. L. The TGF-beta family and its composite receptors. Trends Cell Biol. 4, 172-178 (1994).
54. Sieber, C., Kopf, J., Hiepen, C. & Knaus, P. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev. 20, 343-355 (2009).
55. Wozney, J. M. Overview of bone morphogenetic proteins. Spine (Phila. PA 1976) 27 (16 Suppl. 1), S2-S8 (2002).
56. Cook, S. D. & Rueger, D. C. Osteogenic protein-1: biology and applications. Clin. Orthop. Relat. Res. 324, 29-38 (1996).
57. Merrihew, C. et al. Alterations in endogenous osteogenic protein-1 with degeneration of human articular cartilage. J. Orthop. Res. 21, 899-907 (2003).
58. Nishida, Y., Knudson, C. B. & Knudson, W. Osteogenic protein-1 inhibits matrix depletion in a hyaluronan hexasaccharide-induced model of osteoarthritis. Osteoarthritis Cartilage 12, 374-382 (2004).
59. Jelic, M. et al. Regeneration of articular cartilage chondral defects by osteogenic protein-1 (bone morphogenetic protein-7) in sheep. Growth Factors 19, 101-113 (2001).
60. Cook, S. D., Patron, L. P., Salkeld, S. L. & Rueger, D. C. Repair of articular cartilage defects with osteogenic protein-1 (BMP-7) in dogs. J. Bone Joint Surg. Am. 85?a (Suppl. 3), 116-123 (2003).
61. Sellers, R. S., Peluso, D. & Morris, E. A. The effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) on the healing of full-thickness defects of articular cartilage. J. Bone Joint Surg. Am. 79, 1452-1463 (1997).
62. Dose finding study of bone morphogenetic protein 7 (BMP-7) in subjects with osteoarthritis (OA) of the knee. ClinicalTrials.gov identifier: NCT01111045 [online], http://clinicaltrials. gov/ct2/show/NCT01111045 (2010)
63. White-OConnor, B. & Sobal, J. Nutrient intake and obesity in a multidisciplinary assessment of osteoarthritis. Clin. Ther. 9 (Suppl. B), 30-42 (1986).
64. Lane, N. E. et al. Serum vitamin D levels and incident changes of radiographic hip osteoarthritis: a longitudinal study. Study of Osteoporotic Fractures Research Group. Arthritis Rheum. 42, 854-860 (1999).
65. McAlindon, T. E. et al. Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study. Ann. Intern. Med. 125, 353-359 (1996).
66. Vitamin D to slow progression of knee osteoarthritis. ClinicalTrials.gov identifier: NCT00306774 [online], http://clinicaltrials.gov/ ct2/show/NCT00306774 (2010)
67. Zurich multiple endpoint vitamin D trial in knee OA patients. ClinicalTrials.gov identifier: NCT00599807 [online], http://clinicaltrials.gov/ ct2/show/NCT00599807 (2010)
68. Bello, A. E. & Oesser, S. Collagen hydrolyzate for the treatment of osteoarthritis and other joint disorders: a review of the literature. Curr. Med. Res. Opin. 22, 2221-2232 (2006).
69. Moskowitz, R. W. Role of collagen hydrolyzate in bone and joint disease. Semin. Arthritis Rheum. 30, 87-99 (2000).
70. Adam, M. Therapy for osteoarthritis: which effects have preparations of gelatin- Therapiewoche 38, 2456-2461 (1991).
71. Benito-Ruiz, P. et al. A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolyzate, for improving joint comfort. Int. J. Food Sci. Nutr. 60 (Suppl. 2), 99-113 (2009).
72. A placebo-controlled study of collagen hydrolyzate in subjects with knee osteoarthritis (OA) (NMR). ClinicalTrials.gov identifier: NCT00536302 [online], http://clinicaltrials.gov/ ct2/show/NCT00536302 (2009).
73. Moore, E. E. et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage 13, 623-631 (2005).
74. Ellman, M. B., An, H. S., Muddasani, P. & Im, H. J. Biological impact of the fibroblast growth factor family on articular cartilage and intervertebral disc homeostasis. Gene 420, 82-89 (2008).
75. AS902330 in cartilage injury repair (CIR). ClinicalTrials.gov identifier: NCT01066871 [online], http://clinicaltrials.gov/ct2/show/ NCT01066871 (2010).
76. Henrotin, Y. E. et al. Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes. J. Rheumatol. 30, 1825-1834 (2003).
77. Ernst, E. Avocado-soybean unsaponifiables (ASU) for osteoarthritis-a systematic review. Clin. Rheumatol. 22, 285-288 (2003).
78. Blotman, F., Maheu, E., Wulwik, A., Caspard, H. & Lopez, A. Efficacy and safety of avocado/ soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Rev. Rhum. Engl. Ed. 64, 825-834 (1997).
79. Appelboom, T., Schuermans, J., Verbruggen, G., Henrotin, Y. & Reginster, J. Y. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scand. J. Rheumatol. 30, 242-247 (2001).
80. Maheu, E. et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum. 41, 81-91 (1998).
81. Lequesne, M., Maheu, E., Cadet, C. & Dreiser, R. L. Structural effect of avocado/ soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Rheum. 47, 50-58 (2002).
82. Evaluation of the structure modifying effect of avocado-soybean unsaponifiables in hip osteoarthritis (ERADIAS). ClinicalTrials.gov identifier: NCT01062737 [online], http:// clinicaltrials.gov/ct2/show/NCT01062737 (2010).
83. Rudolphi, K., Gerwin, N., Verzijl, N., van der Kraan, P. & van den Berg, W. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage 11, 738-746 (2003).
84. Zhang, X., Mao, Z. & Yu, C. Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10. J. Orthop. Res. 22, 742-750 (2004).
85. Chevalier, X., Mugnier, B. & Bouvenot, G. Targeted anti-cytokine therapies for osteoarthritis. Bull. Acad. Natl Med. 190, 1411-1420 (2006).
86. Treatment for patients with osteoarthritis (OA). ClinicalTrials.gov identifier: NCT00110942 [online], http://clinicaltrials.gov/ct2/show/ NCT00110942 (2008).
87. Krzeski, P. et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebocontrolled study. Arthritis Res. Ther. 9, R109 (2009).
88. Tu, G., Xu, W., Huang, H. & Li, S. Progress in the development of matrix metalloproteinase inhibitors. Curr. Med. Chem. 15, 1388-1395 (2008).
89. Fingleton, B. Matrix metalloproteinases as valid clinical targets. Curr. Pharm. Des. 13, 333-346 (2007).
90. Johnson, A. R. et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J. Biol. Chem. 282, 27781-27791 (2007).
91. Baragi, V. M. et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum. 60, 2008-2018 (2009).
92. Schett, G. Erosive arthritis. Arthritis Res. Ther. 9 (Suppl. 1), S2 (2007).
93. Salminen-Mankonen, H. J., Morko, J. & Vuorio, E. Role of cathepsin K in normal joints and in the development of arthritis. Curr. Drug Targets 8, 315-323 (2007).
94. Jones, A. R. et al. Binding and localization of recombinant lubricin to articular cartilage surfaces. J. Orthop. Res. 25, 283-292 (2007).
95. Kashiwagi, M., Tortorella, M., Nagase, H. & Brew, K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J. Biol. Chem. 276, 12501-12504 (2001).
96. Glasson, S. S. et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 434, 644-648 (2005).
97. Hunter, D. Focusing osteoarthritis management on modifiable risk factors and future therapeutic prospects. Ther. Ad. Musc. Dis. 1, 35-47 (2009).
98. Hunter, D. J. et al. Change in cartilage morphometry: a sample of the progression cohort of the osteoarthritis initiative. Ann. Rheum. Dis. 68, 349-356 (2009).
99. Karachalios, T. et al. MR imaging findings in early osteoarthritis of the knee. Eur. J. Radiol. 50, 225-230 (2004).
100. Reichenbach, S. et al. Prevalence of bone attrition on knee radiographs and MRI in a community-based cohort. Osteoarthritis Cartilage 16, 1005-1010 (2008).
101. Amin, S. et al. The relationship between cartilage loss on magnetic resonance imaging and radiographic progression in men and women with knee osteoarthritis. Arthritis Rheum. 52, 3152-3159 (2005).
102. Roos, H., Adalberth, T., Dahlberg, L. & Lohmander, L. S. Osteoarthritis of the knee after injury to the anterior cruciate ligament or meniscus: the influence of time and age. Osteoarthritis Cartilage 3, 261-267 (1995).
103. Lohmander, L. S., Ostenberg, A., Englund, M. & Roos, H. High prevalence of knee osteoarthritis, pain, and functional limitations in female soccer players twelve years after anterior cruciate ligament injury. Arthritis Rheum. 50, 3145-3152 (2004).
104. Englund, M., Roos, E. M. & Lohmander, L. S. Impact of type of meniscal tear on radiographic and symptomatic knee osteoarthritis: a sixteenyear followup of meniscectomy with matched controls. Arthritis Rheum. 48, 2178-2187 (2003).
105. Englund, M. & Lohmander, L. S. Risk factors for symptomatic knee osteoarthritis fifteen to twenty-two years after meniscectomy. Arthritis Rheum. 50, 2811-2819 (2004).
106. Andriacchi, T. P., Briant, P. L., Bevill, S. L. & Koo, S. Rotational changes at the knee after ACL injury cause cartilage thinning. Clin. Orthop. Relat. Res. 442, 39-44 (2006).
107. Peterfy, C. G., Schneider, E. & Nevitt, M. The osteoarthritis initiative: report on the design rationale for the magnetic resonance imaging protocol for the knee. Osteoarthritis Cartilage 16, 1433-1441 (2008).
108. Spector, T. D. et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res. Ther. 7, R625-R633 (2005).
109. Bingham, C. O. 3rd et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum. 54, 3494-3507 (2006).
110. Clegg, D. O. et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N. Engl. J. Med. 354, 795-808 (2006).
111. Reginster, J. Y. et al. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357, 251-256 (2001).
112. Pavelká, K. et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, doubleblind study. Arch. Intern. Med. 162, 2113-2123 (2002).
113. Kahan, A., Uebelhart, D., De Vathaire, F., Delmas, P. D. & Reginster, J. Y. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 60, 524-533 (2009).
114. Raynauld, J. P. et al. Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicenter clinical trial using quantitative MRI. Ann. Rheum. Dis. 68, 938-947 (2009).
115. Listrat, V. et al. Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee. Osteoarthritis Cartilage 5, 153-160 (1997).
116. Jubb, R. W., Piva, S., Beinat, L., Dacre, J. & Gishen, P. A one-year, randomised, placebo (saline) controlled clinical trial of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. Int. J. Clin. Pract. 57, 467-474 (2003).